Project Scope

To understand the access challenges and price potential for a product for ATTR (amyloid transthyretin) in adult patients

Challenge

Our client plans to launch a new product for hATTR treatment in adult PN patients, with future expansion to wtATTR or hATTR in adult CM patients. They seek insights on treatment approaches in the UAE and KSA, assessing evidence package value and pricing for launch and indication expansion

Solution

Conducted primary market research to understand:

• The perception of evidence for Product X and likely HTA outcome in ATTR-PN and ATTR-CM
• The price potential, the impact of different scenarios on price, whether discounting and innovative contracting may offer useful differentiation strategies
• Payers’ perceptions of the current landscape and unmet need

Results

Successfully enabled our client to understand:

• The perceived advantages and weaknesses of the evidence package
• Expected access restrictions and factors which may limit uptake
• Potential list price (first indication) and how it may be affected by an indication expansion
• The feasibility and willingness to set managed entry agreements